Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) was submitted on May 13, 2019. The document serves as a Block Listing Six Monthly Return detailing the status of four specific employee share incentive schemes for the period from November 1, 2018, to April 30, 2019.
Key Financial Metrics
The filing does not provide financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document is strictly limited to reporting the movement of securities under specific equity compensation plans.
Material Changes in Equity Schemes
The filing reports the following changes in unallotted securities across four schemes during the six-month period:
- 2009 Deferred Annual Bonus Plan: 393,607 securities were issued/allotted, reducing the unallotted balance from 547,331 to 153,724.
- Share Option Plan - Ordinary Shares: 958,344 securities were issued/allotted, reducing the unallotted balance from 2,223,352 to 1,265,008.
- Share Option Plan - ADS: 1,424,800 securities were issued/allotted, reducing the unallotted balance from 7,336,096 to 5,911,296.
- Share Save Plan 2012: 3,345,727 securities were issued/allotted, reducing the unallotted balance from 5,672,623 to 2,326,896.
No increases were applied to the block schemes during this period.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, financial guidance, outlook, risk factors, contingencies, or unusual items. The document is a regulatory compliance report regarding share plan administration.
Key Facts for Investor Verification
- Verify the total number of shares issued under the Share Save Plan 2012 (3,345,727) as this represents the largest single issuance among the reported schemes.
- Confirm the remaining unallotted balances for the Share Option Plan - ADS (5,911,296) and Share Save Plan 2012 (2,326,896) to assess future dilution potential.
- Note that no new securities were added to the block limits of any scheme during the reporting period.